NCT04326725 - Proflaxis Using Hydroxychloroquine Plus Vitamins-Zinc During COVID-19 Pandemia | Crick

Overview

Healthcare professionals mainly doctors, nurses and their first degree relatives (spouse, father, mother, sister, brother, child) who have been started hydroxychloroquine(plaquenil) 200mg single dose repeated every three weeks plus vitaminC including zinc once a day were included in the study. Study has conducted on 20th of march. Main purpose of the study was to cover participants those who are facing or treating COVID19 infected patients in Ankara.

Healthcare professionals mainly doctors, nurses and their first degree relatives (spouse, father, mother, sister, brother, child) who have been started hydroxychloroquine(plaquenil) 200mg single dose repeated every three weeks plus vitaminC including zinc once a day were included in the study. Study has conducted on 20th of march. Main purpose of the study was to cover participants those who are facing or treating COVID19 infected patients.PArticipants, age, sex, BMI, smoking history, comorbid disease were also registered.

Study Type

OBSERVATIONAL

Enrollment

80

Conditions

Pneumonitis Coronavirus Infection

Interventions

Plaquenil 200Mg TabletDRUG

health workers under risk who took this medications

Eligibility

Sex: ALLMin age: 20 YearsMax age: 90 YearsHealthy volunteers:

Medical Language ↔ Plain English

Inclusion Criteria: 1. person who are working as health professional with contact to known COVID positive case 2. Their first degree relatives (child, spouse or parents) 3. must be able to swallow tablets Exclusion Criteria: 1. Already using plaquenil for other reasons (RA etc) 2. person with the diagnosis of COVID infection 3. Person with the condition may cause complications with this medication (severe CVD, av block, already has ophtalmological complications, organ failure of any degree etc). 4. Documented allergic history to chloroquine; 5. Documented history of hematological system diseases; 6. Documented history of chronic liver and kidney diseases; 7. Documented history of cardiac arrhythmia or chronic heart diseases; 8. Documented history of retina or hearing dysfunction; 9. Documented history of mental illnesses; 10. Use of digitalis due to the previous disease.

Locations (1)

Istinye University Medical School

Istanbul, Turkey (Türkiye)

Outcomes

Primary Outcomes

Protection against COVID-19

persons who took this medication should not have an infection

Time frame: 4 months